In this issue, 2 articles from opposite sides of the globe explore aspects of the motivations of cancer patients who employ complementary and alternative medicine (CAM). Both articles are based on qualitative research, a design that uses systematic analyses of the words of the subjects themselves, who participate in lengthy, face-to-face interviews with investigators. Although these studies lack the purported assurance of the randomized trial, what they do offer, when conducted methodically and systematically, may be of equal and profound value. Through the semistructured or open interview format, qualitative research produces information that would not be revealed and, in fact, would never be captured if subjects were constrained in their responses by the set of predetermined thought constructs or operational variables found in standardized questionnaires. By providing a window into the feelings and perceptions of patients, which drive an essential aspect of medical care, we can gain access and essential insights into the patient's personal perspective and experience at a deeper level. This aspect of patient care is rarely clarified and can even be lost by evidence-based standards and guidelines. Qualitative studies, which customarily quote statements directly from the research interviews, allow patients a literal voice. It is this voice and, thus, a keener grasp of the patient's authentic experience that is of profound value to practitioners and patients alike, enlarging the important therapeutic alliance.
Harvir Singh and colleagues report on a study of a multiethnic population of prostate cancer patients in Hawaii, exploring motivational issues among a group of patients using CAM and a group that had not. The major motivations of these 2 groups are different. The group of patients who had not used CAM expressed positive assessments of conventional treatment for removing the tumor and for having FDA-approved medical treatments and a scientific approach; they found the side effects, including impotence, to be acceptable. The CAM group, on the other hand, found side effects to be a major concern and appreciated the emphasis of CAM on improving the body's capacity to heal. What I find particularly relevant about this study is the attitude expressed by some of the CAM-using patients about the use of "watchful waiting" in early-stage prostate cancer. They felt that it was better to take action and attempt to exercise some control, rather than simply to monitor the disease as passive observers. This is concordant with the approach of integrative medicine and illustrates how integrative treatments may meet the needs of patients at many levels. It is also important to keep in mind the real value of the inclusion of patients from multiple ethnic groups in this study.
The study by Aslak Steinsbekk and Laila Launsø examines the experiences of Norwegian cancer patients who consulted with both CAM and conventional practitioners. Its main focus is on the character of the consultations, but it reveals some aspects of motivation. Patients reported, for instance, distress in talking to practitioners who undermined hope with undiluted prognostic news, whereas they expressed comfort with physicians who maintained a more positive approach and with CAM practitioners who increased hope by discussing examples of patients who had done well. Struggles about breaking or hearing bad news in cancer, discussed in the pages of this journal before, 1 appear to be international. The Norwegian patients also remarked on the body language of physicians who never looked up from their medical records and who took no notes: these conveyed the impression that what mattered were only the lab results and not the patients. CAM practitioners were described as more likely to listen to the patients' stories and to take a comprehensive approach to their health. Although none of these observations is surprising, it is interesting to see the global reach of the phenomenon of interest in alternative and complementary medical approaches. The reminders to physicians and other practitioners of ways to better serve the personal and emotional needs of patients are critical to more effective clinical care and possibly to improved patient adherence.
A third article, by frequent contributor Alastair Cunningham, also gives us ample opportunity to listen to the words of cancer patients-in this case, patients speaking about a topic of emerging research interest: spirituality in cancer. This study is not qualitative in design; rather, cancer patients participating in a psychoeducational course on spirituality were evaluated using standard psychometric tests such as the Profile of Mood States, the Purpose in Life Test, and the FACIT-Sp, a quality-of-life test assessing spiritual wellbeing. These tests, however, are supplemented with substantial quotations from the written "homework" Editorial done by patients in the course. Although it is customary to present only objective data from validated tests in studies of this sort, our reviewers felt that the power and dimension added by the extensive quotations significantly increased the value of Cunningham's article. Because the topic of spirituality in cancer is so new, it is not possible to consider the existing instruments for measuring as the final word on important dimensions in this area. Researchers as well as practitioners in the field of spirituality, whose patients wrestle daily with the spiritual implications of chronic or terminal disease, can profit by a careful reading of Cunningham's article.
This issue opens with a comprehensive review by Kenneth Conklin on the important topic of the use of co-Q10 in preventing cardiac damage caused by anthracycline therapy. Conklin shows his detailed understanding of the biochemistr y of both antineoplastic agents and antioxidants in evaluating the mechanisms of this useful agent, providing a sound rationale for its effectiveness. Conklin previously discussed antioxidants and antineoplastic therapy in the December 2004 special issue of Integrative Cancer Therapies, sharing a comprehensive and innovative review of the biochemistry of cytotoxic drugs with our readers. 2 Dugald Seely and colleagues from the Canadian College of Naturopathic Medicine, the University of Toronto, McMaster University, and the London School of Tropical Hygiene present a systematic review of the effect of green tea on breast cancer incidence and recurrence. They use very large cohort studies of breast cancer incidence and smaller cohort studies of breast cancer recurrence, in addition to case-control studies of incidence, all of them from Japan and China, where green tea consumption is higher than in Western countries. One particularly encouraging aspect of this study is the apparent degree of collaboration between a college of naturopathic medicine and experts in the area in major universities. Collaboration between training institutions in fields such as naturopathy, chiropractic, and oriental medicine and universities that are strong in the area of conventional medicine is a development that should add immensely to the relevance of training on both sides.
Andrea Cohen and colleagues from the Complementary and Alternative Medicine Research Center at the University of Colorado Cancer Center have contributed a review of the potential uses of acupuncture in treating conditions related to cancer, including nausea induced by chemotherapy, depression, breathlessness, xerostomia, and hot flashes. They also provide a useful brief review on the history and physiology of acupuncture, specifically aimed at conventional oncologists who may have limited exposure in this field. Although many of the studies included for this review are limited in size and design, the large effect sizes they report strengthen the case for increasing research on acupuncture as a means of controlling distressing side effects and symptoms related to cancer treatment or progression.
Finally, 2 articles in this issue specifically address treatments in alternative medicine clinics. A best case series review of the Hufeland Klinik in Germany is presented by Judith Jacobson and colleagues at Columbia University, including Alfred I. Neugut, the head of Cancer Prevention and Control at the Herbert Irving Comprehensive Cancer Center. The best case series is one of the mechanisms adopted by the National Cancer Institute's Office of Cancer Complementary and Alternative Medicine for evaluating the possible usefulness of CAM clinics. The Hufeland Klinik program includes dietary modification, injections, ozone therapy, active fever therapy, and psychotherapy, as well as some conventional therapy. The thorough and objective review provided by the Columbia University team and the detailed data they present in this study are a model for researchers interested in using the best case technique for evaluating other alternative clinics.
Stanislaw Burzynski and colleagues at the Burzynski Clinic, who have published previously in Integrative Cancer Therapies, have been conducting phase I and phase II trials super vised by the FDA on antineoplaston therapy. The article in this issue presents results on 13 pediatric brain tumor patients selected from 2 different trials. This case series represents the patients with primitive neuroectodermal tumors, including medulloblastoma and pineoblastoma and related tumors. Besides detailed information on the cases, Burzynski and colleagues present an interesting analysis of the molecular targets involved in the biochemistry of the antineoplaston treatments.
The topics in this issue thus range from the level of the spirit to that of the molecule. Integrative cancer care necessarily takes into account the reality and relevance of all these levels. It is a challenging menu for the practitioner, but those of us on the editorial staff of Integrative Cancer Therapies hope that by continuing to expose readers to every facet of care, we will improve the care and lives of cancer patients globally.
